PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Anti-PD-1)/programmed cell death-ligand 1 (PD-L1) antibody plus platinum-based chemotherapy (PBC) has replaced PBC as first-line treatment for patients with non-squamous (sq) non-small cell lung cancer (NSCLC) lacking targetable driver mutations. However, few studies have directly compared immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Hui, Chen, Ping, Xia, Liangping, Fu, Sha, Chen, Chen, Zhang, Xuanye, He, Lina, Zhang, Bei, Zhou, Yixin, Hong, Shaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576478/
https://www.ncbi.nlm.nih.gov/pubmed/34750245
http://dx.doi.org/10.1136/jitc-2021-003431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576478/
https://www.ncbi.nlm.nih.gov/pubmed/34750245
http://dx.doi.org/10.1136/jitc-2021-003431

Ejemplares similares